HNGE Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 -2.41%, SMA50 -1.13%, SMA200 -2.84%). The stock’s 14-day RSI is 46.63 (neutral), while the ATR of 2.02 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -24.01% below its high and over 41.37% above its low. Average 10-day trading volume of 1.04 million shares is below the 3-month average of 1.53 million, indicating normal recent market interest.

Hinge Health, Inc. (NYSE:HNGE) closed at $48.64 USD, gaining $1.40 (2.95%) from the previous close of $47.24. The stock is currently mid-range between its 52-week high and low $33.42 and $62.18. With a market capitalization of about $3.83 billion, Hinge Health, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~4.72). Key stats such as the average daily volume over the past year has been around 1.56 million shares, volume is running light vs its 52-week average. Headquartered in San Francisco, CA, Hinge Health, Inc. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Daniel A. Perez, the company employs approximately 1,514 people and listed since May 22, 2025. Hinge Health, Inc. develops health care software for joint and muscle health.

Hinge Health, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.26. This means the shares are trading above this model’s fair value.

Hinge Health, Inc. has 27.22 million shares outstanding. The public float is 21.69 million shares, elevated short interest at 4.32% of float. This equals 1.12 million shares. The short ratio is 1.4 days. Institutional investors hold 171.0% of the float. Insiders own 22.87%. Bessemer Venture Partners X L.P. holds 3.38 million shares, Pursley James has 789.90 thousand shares and Budge James has 479.88 thousand shares. Over the past six months, insider transactions show net selling. They sold 874.07 thousand shares across 12 transactions.

Analyst sentiment is bullish. Analyst rating data shows there are 17 Strong Buy ratings, 11 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $71.00 to $41.00. The high target offers 50.26% upside. The low target suggests -13.23% downside. The mean target is $55.48. This offers 17.42% upside. Hinge Health, Inc. earnings surprise history is a mixed track record. The quarter that ended November 04, 2025, missed forecasts by 41.67%. The prior quarter beat by 644.44%. Over the last six quarters, Apple has recorded several small beats. These include 644.44% in August 05, 2025.

currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Hinge Health, Inc. trading at a premium to the broader market with a P/E of -7.17. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $55.48, suggesting 17.42% upside. Our AI forecast model points to short-term strength (4.34% over two weeks), a medium-term fall (-74.56% over three months), and a longer-term loss (-49.21% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Hinge Health, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.34%, with price expected at $49.30 by January 02, 2026, within a range of $46.29 to $52.42 3-Month Outlook: Projected fall of -74.56%, reaching $12.02 by March 19, 2026, with a range of $11.21 to $12.94. 1-Year Outlook: Projected loss of -49.21%, with price at $24.00 by December 18, 2026, within a range of $20.60 to $28.17.

Hinge Health, Inc. trades at a P/E ratio of -7.17, slightly below the S&P 500 average, with a price-to-sales ratio of 7.14 and a price-to-book ratio of 9.38 trading at moderately above to book value. The P/FCF stands at 28.93, also above market averages.